摘要
目的研究影响拉米夫定治疗慢性乙型肝炎疗效的因素。方法对109例HBeAg阳性慢性乙型肝炎患者分别于治疗前、治疗4、12、24和48周时对ALT水平,HBV DNA和HBeAg定量进行检测,并在治疗24周和48周时对HBeAg血清转换率进行分析。结果治疗前ALT≥3×ULN,HBV DNA<4.2×106拷贝/ml,出现早期病毒学应答者HBeAg血清转换率较高(P<0.01或<0.05)。结论治疗前较高的ALT水平,较低的HBV DNA定量值及出现早期病毒学应答是影响拉米夫定治疗慢性乙型肝炎疗效的主要因素。
Objective To study the efficacy of lamivudine for chronic hepatitis B. Methods To test ALT level, HBV DNA and HBeAg ration in 109 patients who are HBeAg positive before the treatment, 4, 12, 24 and 48 weeks after the treatment, and analyse the HBeAg after 24 and 48 weeks treatment. Results Those ALT 〉 3 ×ULN, HBV DNA 〈 4.2 ×10^6 copies/ml before the treatment, and with virus response at an early stage have a high HBeAg seroconversion （P 〈0,01 or 〈 0.05）.Condusions The relatively high ALT level, low HBV DNA ration and early virus response are the major factors that affect the curative effect of lamivudine in treating chronic hepatitis B.
